{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:20:33Z","timestamp":1788258033466,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"cnpq","award":["409700\/2022-3, 310349\/2021, 401870\/2020"],"award-info":[{"award-number":["409700\/2022-3, 310349\/2021, 401870\/2020"]}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"crossref","award":["(1036\/2022, 003\/2020, 300\/2021, 113\/2021, 442\/2021, 492\/2021, 165\/2021"],"award-info":[{"award-number":["(1036\/2022, 003\/2020, 300\/2021, 113\/2021, 442\/2021, 492\/2021, 165\/2021"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006182","name":"FAPES","doi-asserted-by":"crossref","award":["(1036\/2022, 003\/2020, 300\/2021, 113\/2021, 442\/2021, 492\/2021, 165\/2021"],"award-info":[{"award-number":["(1036\/2022, 003\/2020, 300\/2021, 113\/2021, 442\/2021, 492\/2021, 165\/2021"]}],"id":[{"id":"10.13039\/501100006182","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fabry disease (FD) is a rare X-linked lysosomal storage disorder marked by alpha-galactosidase-A (\u03b1-Gal A) deficiency, caused by pathogenic mutations in the\n                      <jats:italic>GLA<\/jats:italic>\n                      gene, resulting in the accumulation of glycosphingolipids within lysosomes. The current screening test relies on measuring \u03b1-Gal A activity. However, this approach is limited to males. Infrared (IR) spectroscopy is a technique that can generate fingerprint spectra of a biofluid\u2019s molecular composition and has been successfully applied to screen numerous diseases. Herein, we investigate the discriminating vibration profile of plasma chemical bonds in patients with FD using attenuated total reflection Fourier-transform IR (ATR-FTIR) spectroscopy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The Fabry disease group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947) and the healthy control group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200952) recruited were age-matched (39.2\u2009\u00b1\u200916.9 and 36.7\u2009\u00b1\u200910.9 years, respectively), and females were predominant in both groups (59.6% and 65.4%, respectively). All patients had the classic phenotype (100%), and no late-onset phenotype was detected. A generated partial least squares discriminant analysis (PLS-DA) classification model, independent of gender, allowed differentiation of samples from FD vs. control groups, reaching 100% sensitivity, specificity and accuracy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ATR-FTIR spectroscopy harnessed to pattern recognition algorithms can distinguish between FD patients and healthy control participants, offering the potential of a fast and inexpensive screening test.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-024-03380-x","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T03:01:59Z","timestamp":1728529319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Infrared spectroscopy as a new approach for early fabry disease screening: a pilot study"],"prefix":"10.1186","volume":"19","author":[{"given":"Carolina Teles","family":"Barretto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia Helena Cassago","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Ferro","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Barcelos","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Augusto Costa","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassiano Augusto Braga","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneesh N.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Roberto","family":"Filgueiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanderson","family":"Rom\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciene Cristina Gastalho","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2832-0922","authenticated-orcid":false,"given":"Valerio Garrone","family":"Barauna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"3380_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. https:\/\/doi.org\/10.1186\/1750-1172-5-30","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"3380_CR2","first-page":"790","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with fabry disease: findings from the Fabry Registry. Genet Sci. 2009;11(11):790\u20136.","journal-title":"Genet Sci"},{"key":"3380_CR3","doi-asserted-by":"publisher","unstructured":"Desnick RJ. Fabry disease: \u03b1-galactosidase A deficiency. Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease. Academic; 2020. pp. 575\u201387. https:\/\/doi.org\/10.1016\/B978-0-12-813955-4.00042-8","DOI":"10.1016\/B978-0-12-813955-4.00042-8"},{"issue":"2","key":"3380_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.gene.2012.06.01","volume":"505","author":"D Elstein","year":"2012","unstructured":"Elstein D, Schachamorov E, Beeri R, Altarescu G. X-inactivation in fabry disease. Gene. 2012;505(2):266\u20138. https:\/\/doi.org\/10.1016\/j.gene.2012.06.01","journal-title":"Gene"},{"key":"3380_CR5","doi-asserted-by":"publisher","unstructured":"Curiati MA, Aranda CS, Kyosen SO, et al. The challenge of diagnosis and indication for treatment in Fabry Disease. J Inborn Errors Metabolism Screen. 2017;5. https:\/\/doi.org\/10.1177\/2326409816685735","DOI":"10.1177\/2326409816685735"},{"issue":"4","key":"3380_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/cge.14102","volume":"101","author":"DP Germain","year":"2022","unstructured":"Germain DP, Levade T, Hachulla E, Knebelmann B, Lacombe D, Seguin VL, Nguyen K, No\u00ebl E, Rab\u00e8s JP. Challenging the traditional approach for interpreting genetic variants: lessons from fabry disease. Clin Genet. 2022;101(4):390\u2013402. https:\/\/doi.org\/10.1111\/cge.14102","journal-title":"Clin Genet"},{"issue":"1","key":"3380_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408363.2017.1414142","volume":"55","author":"S De Bruyne","year":"2018","unstructured":"De Bruyne S, Speeckaert MM, Delanghe JR. Applications of mid-infrared spectroscopy in the clinical laboratory setting. Crit Rev Clin Lab Sci. 2018;55(1):1\u201320. https:\/\/doi.org\/10.1080\/10408363.2017.1414142","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"10","key":"3380_CR8","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.3390\/ijms23105345","volume":"23","author":"E Tolstik","year":"2022","unstructured":"Tolstik E, et al. CARS imaging advances early diagnosis of cardiac manifestation of fabry disease. Int J Mol Sci. 2022;23(10):5345. https:\/\/doi.org\/10.3390\/ijms23105345","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3380_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/cancers12010115","volume":"12","author":"KY Su","year":"2020","unstructured":"Su KY, Lee WL. Fourier transform infrared spectroscopy as a cancer screening and diagnostic tool: a review and prospects. Cancers. 2020;12(1):115. https:\/\/doi.org\/10.3390\/cancers12010115","journal-title":"Cancers"},{"key":"3380_CR10","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1038\/s41467-019-12527-5","volume":"10","author":"HJ Butler","year":"2019","unstructured":"Butler HJ, Brennan PM, Cameron JM, et al. Development of high-throughput ATR-FTIR technology for rapid triage of brain cancer. Nat Commun. 2019;10:4501. https:\/\/doi.org\/10.1038\/s41467-019-12527-5","journal-title":"Nat Commun"},{"issue":"5","key":"3380_CR11","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1021\/acs.analchem.1c04162","volume":"94","author":"MH Nascimento","year":"2022","unstructured":"Nascimento MH, Marcarini WD, Folli GS, da Silva Filho WG, Barbosa LL, et al. Noninvasive diagnostic for COVID-19 from saliva biofluid via FTIR spectroscopy and multivariate analysis. Anal Chem. 2022;94(5):2425\u201333. https:\/\/doi.org\/10.1021\/acs.analchem.1c04162","journal-title":"Anal Chem"},{"issue":"5","key":"3380_CR12","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1021\/acs.analchem.0c04608","volume":"93","author":"VG Barauna","year":"2021","unstructured":"Barauna VG, Singh MN, Barbosa LL, Marcarini WD, Vassallo PF, et al. Ultrarapid on-site detection of SARS-CoV-2 infection using simple ATR-FTIR spectroscopy and an analysis algorithm: high sensitivity and specificity. Anal Chem. 2021;93(5):2950\u20138. https:\/\/doi.org\/10.1021\/acs.analchem.0c04608","journal-title":"Anal Chem"},{"issue":"1","key":"3380_CR13","doi-asserted-by":"publisher","first-page":"15409","DOI":"10.1038\/s41598-021-93511-2","volume":"11","author":"MS Nogueira","year":"2021","unstructured":"Nogueira MS, Leal LB, Marcarini WD, et al. Rapid diagnosis of COVID-19 using FT-IR ATR spectroscopy and machine learning. Sci Rep. 2021;11(1):15409. https:\/\/doi.org\/10.1038\/s41598-021-93511-2","journal-title":"Sci Rep"},{"key":"3380_CR14","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1007\/s12011-020-02510-3","volume":"199","author":"LB Leal","year":"2021","unstructured":"Leal LB, Nogueira MS, Mageski JGA, et al. Diagnosis of systemic diseases using infrared spectroscopy: detection of iron overload in plasma\u2014preliminary study. Biol Trace Elem Res. 2021;199:3737\u201351. https:\/\/doi.org\/10.1007\/s12011-020-02510-3","journal-title":"Biol Trace Elem Res"},{"key":"3380_CR15","doi-asserted-by":"publisher","first-page":"102312","DOI":"10.1016\/j.pdpdt.2021.102312","volume":"34","author":"GC Pinto","year":"2021","unstructured":"Pinto GC, Leal LB, Magalh\u00e3es NC, Pereira MF, Vassallo PF, Pereira TM, et al. The potential of FT-IR spectroscopy for improving healthcare in sepsis\u2013An animal model study. Photodiagnosis Photodyn Ther. 2021;34:102312. https:\/\/doi.org\/10.1016\/j.pdpdt.2021.102312","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"4","key":"3380_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1177\/00037028231156194","volume":"77","author":"RA Faria","year":"2023","unstructured":"Faria RA, Leal LB, Thebit MM, et al. Role of Fourier Transform Infrared Spectroscopy as a Screening Approach for breast Cancer. Appl Spectrosc. 2023;77(4):405\u201317. https:\/\/doi.org\/10.1177\/00037028231156194","journal-title":"Appl Spectrosc"},{"issue":"7","key":"3380_CR17","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1039\/C4AN01942C","volume":"140","author":"C Lacombe","year":"2015","unstructured":"Lacombe C, Untereiner V, Gobinet C, Zater M, Sockalingum GD, Garnotel R. Rapid screening of classic galactosemia patients: a proof-of-concept study using high-throughput FTIR analysis of plasma. Analyst. 2015;140(7):2280\u20136. https:\/\/doi.org\/10.1039\/C4AN01942C","journal-title":"Analyst"},{"issue":"4","key":"3380_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000448740","volume":"134","author":"CAB Silva","year":"2016","unstructured":"Silva CAB, Barreto FC, dos Reis MA, Moura Junior JA, Cruz CMS. Targeted screening of fabry disease in male hemodialysis patients in Brazil highlights importance of family screening. Nephron. 2016;134(4):221\u201330. https:\/\/doi.org\/10.1159\/000448740","journal-title":"Nephron"},{"issue":"1","key":"3380_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340. https:\/\/doi.org\/10.1086\/504601","journal-title":"Am J Hum Genet"},{"issue":"8","key":"3380_CR20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/jhg.2013.48","volume":"58","author":"T Inoue","year":"2013","unstructured":"Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S. Newborn screening for fabry disease in Japan: prevalence and genotypes of fabry disease in a pilot study. J Hum Genet. 2013;58(8):548\u201352. https:\/\/doi.org\/10.1038\/jhg.2013.48","journal-title":"J Hum Genet"},{"issue":"2","key":"3380_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","volume":"121","author":"M Arends","year":"2017","unstructured":"Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, et al. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical fabry disease. Mol Genet Metab. 2017;121(2):157\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2017.05.001","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"3380_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of fabry disease heterozygotes. Mol Genet Metab. 2017;120(1\u20132):57\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2016.10.006","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3380_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","volume":"7","author":"M Niemann","year":"2014","unstructured":"Niemann M, Rolfs A, St\u00f6rk S, Bijnens B, Breunig F, Beer M, Ertl G, Wanner C, Weidemann F. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines fabry disease. Circ Cardiovasc Genet. 2014;7(1):8\u201316. https:\/\/doi.org\/10.1161\/CIRCGENETICS.113.000249","journal-title":"Circ Cardiovasc Genet"},{"key":"3380_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"1802","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Vd Bergh Weerman MA, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of fabry disease. Biochim Biophys Acta. 2010;1802:741\u20138. https:\/\/doi.org\/10.1016\/j.bbadis.2010.05.003","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"3380_CR25","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of fabry disease. Proc Natl Acad Sci U S A. 2008;105(8):2812\u20137. https:\/\/doi.org\/10.1073\/pnas.0712309105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3380_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","volume":"52","author":"BE Smid","year":"2015","unstructured":"Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CE, Poorthuis BJ. Plasma globotriaosylsphingosine in relation to phenotypes of fabry disease. J Med Genet. 2015;52(4):262\u20138. https:\/\/doi.org\/10.1136\/jmedgenet-2014-102872","journal-title":"J Med Genet"},{"issue":"6","key":"3380_CR27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/1873-3468.12104","volume":"590","author":"MJ Ferraz","year":"2016","unstructured":"Ferraz MJ, Marques ARA, Appelman MD, Verhoek M, Strijland A, Mirzaian M, et al. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases. FEBS Lett. 2016;590(6):716\u201325. https:\/\/doi.org\/10.1002\/1873-3468.12104","journal-title":"FEBS Lett"},{"issue":"1","key":"3380_CR28","doi-asserted-by":"publisher","first-page":"15277","DOI":"10.1038\/s41598-019-51805-6","volume":"9","author":"K Xiao","year":"2019","unstructured":"Xiao K, Lu D, Hoepfner J, Santer L, Gupta S, Pfanne A, et al. Circulating microRNAs in fabry disease. Sci Rep. 2019;9(1):15277. https:\/\/doi.org\/10.1038\/s41598-019-51805-6","journal-title":"Sci Rep"},{"issue":"3","key":"3380_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1136\/jmedgenet-2020-107086","volume":"59","author":"A Nowak","year":"2022","unstructured":"Nowak A, Haddad G, Kistler AD, Nlandu-Khodo S, Beuschlein F, W\u00fcthrich RP, et al. Circular RNA-based biomarkers in blood of patients with fabry disease and related phenotypes. J Med Genet. 2022;59(3):279\u201386. https:\/\/doi.org\/10.1136\/jmedgenet-2020-107086","journal-title":"J Med Genet"},{"issue":"8","key":"3380_CR30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/metabo12080703","volume":"12","author":"MT Rocchetti","year":"2022","unstructured":"Rocchetti MT, Spadaccino F, Catalano V, Zaza G, Stallone G, Fiocco D, et al. Metabolic fingerprinting of Fabry Disease: diagnostic and prognostic aspects. Metabolites. 2022;12(8):703. https:\/\/doi.org\/10.3390\/metabo12080703","journal-title":"Metabolites"},{"key":"3380_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-02150-3","volume":"16","author":"JL Jefferies","year":"2021","unstructured":"Jefferies JL, Spencer AK, Lau HA, Nelson MW, Giuliano JD, Zabinski JW, et al. A new approach to identifying patients with elevated risk for fabry disease using a machine learning algorithm. Orphanet J Rare Dis. 2021;16:1\u20138. https:\/\/doi.org\/10.1186\/s13023-021-02150-3","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3380_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/05704928.2020.1738453","volume":"56","author":"K Naseer","year":"2021","unstructured":"Naseer K, Ali S, Qazi J. ATR-FTIR spectroscopy as the future of diagnostics: a systematic review of the approach using bio-fluids. Appl Spectrosc Rev. 2021;56(2):85\u201397. https:\/\/doi.org\/10.1080\/05704928.2020.1738453","journal-title":"Appl Spectrosc Rev"},{"issue":"5","key":"3380_CR33","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1039\/B922045C","volume":"135","author":"ZM Zhang","year":"2010","unstructured":"Zhang ZM, Chen S, Liang YZ. Baseline correction using adaptive iteratively reweighted penalized least squares. Analyst. 2010;135(5):1138\u201346. https:\/\/doi.org\/10.1039\/B922045C","journal-title":"Analyst"},{"issue":"8","key":"3380_CR34","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1021\/ac60214a047","volume":"36","author":"A Savitzky","year":"1964","unstructured":"Savitzky A, Golay MJ. Smoothing and differentiation of data by simplified least squares procedures. Anal Chem. 1964;36(8):1627\u201339. https:\/\/doi.org\/10.1021\/ac60214a047","journal-title":"Anal Chem"},{"issue":"16","key":"3380_CR35","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1039\/c3ay40582f","volume":"5","author":"D Ballabio","year":"2013","unstructured":"Ballabio D, Consonni V. Classification tools in chemistry. Part 1: linear models. PLS-DA Anal Methods. 2013;5(16):3790\u20138. https:\/\/doi.org\/10.1039\/c3ay40582f","journal-title":"PLS-DA Anal Methods"},{"key":"3380_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/00401706.1969.10490666","volume":"11","author":"R Kennard","year":"1969","unstructured":"Kennard R, Stone L. Computer aided design of experiments. Technometrics. 1969;11:137\u201348. https:\/\/doi.org\/10.1080\/00401706.1969.10490666","journal-title":"Technometrics"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03380-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03380-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03380-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T15:06:50Z","timestamp":1728572810000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03380-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3380"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03380-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4638962\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Research Ethics Review Committee of the State University of Santa Cruz (UESC) Ethics Committee, No. 36894020.4.0000.5526.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following competing financial interests: F. L. M. and M. N. S. hold a position and shareholdings in Biocel UK Ltd.; Carolina Teles Barretto has received travel support from Sanofi. Cassiano Augusto Braga e Silva has received travel support and speaker fees from Sanofi and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}